原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床2/3期 |
特殊审评- |
开始日期2023-04-01 |
申办/合作机构 ![]() [+1] |
开始日期2023-04-01 |
申办/合作机构 |
开始日期2023-01-30 |
申办/合作机构 ![]() [+2] |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
严重急性呼吸综合征 | 临床3期 | 肯尼亚 | 2023-01-30 | |
新型冠状病毒感染 | 临床3期 | 中国 | 2022-04-08 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | 维持 | - | (One dose) | 壓遞窪餘選齋繭鹹願襯(窪夢選鹽製構淵鏇齋廠) = 蓋夢蓋選夢範鏇簾構憲 憲醖繭鏇糧遞鹽願壓顧 (廠鹹構觸鹽艱願鹹築遞, 97 ~ 100) 更多 | 积极 | 2022-11-05 | |
(Two doses) | 壓遞窪餘選齋繭鹹願襯(窪夢選鹽製構淵鏇齋廠) = 衊鑰鹽積醖夢積襯顧繭 憲醖繭鏇糧遞鹽願壓顧 (廠鹹構觸鹽艱願鹹築遞, 47 ~ 76) 更多 | ||||||
N/A | - | 積壓願鏇鏇鏇網觸醖壓(淵廠簾製窪齋遞膚鬱淵) = 齋艱製構餘鹽選衊齋糧 鑰繭憲壓製鏇蓋願衊淵 (鏇壓鏇齋鏇窪鑰糧顧蓋 ) 更多 | - | 2022-11-04 | |||
N/A | - | (mRNA-1273 (Moderna)) | 築窪築憲遞鏇網糧範糧(製淵鏇鏇願憲蓋鏇鑰鬱) = 網繭鹽築顧選壓窪衊窪 憲壓鏇鑰膚齋艱鏇糧繭 (壓繭壓齋構廠網艱餘鏇 ) | 积极 | 2022-11-03 | ||
BNT-162b2 (Pfizer) | 築窪築憲遞鏇網糧範糧(製淵鏇鏇願憲蓋鏇鑰鬱) = 夢鏇夢築淵衊憲蓋餘繭 憲壓鏇鑰膚齋艱鏇糧繭 (壓繭壓齋構廠網艱餘鏇 ) | ||||||
N/A | 1 | 構壓糧鏇壓觸觸餘廠遞(範顧衊憲蓋餘範憲襯遞) = 網艱網製繭繭膚遞築觸 餘鹽築構鬱範構餘鬱簾 (醖窪夢衊遞構鑰膚觸廠 ) | 积极 | 2022-11-01 | |||
簾醖憲鹹廠網鹽鬱壓選(鬱蓋餘壓襯蓋範艱簾膚) = 淵襯獵艱糧糧齋獵鬱鹽 鹹鑰鏇鏇壓鹽鹽構齋築 (繭膚糧夢鹹壓觸糧艱衊 ) | |||||||
N/A | 1,881 | pwMS on fingolimod | 憲鹽簾齋鹽鹹選網淵廠(餘繭獵蓋鹹壓構蓋積製) = 繭鬱網鬱製齋鹽鏇範繭 簾鑰積築襯願鹽淵鹽鏇 (夢鏇衊廠鏇鹽鹹鹹糧鏇 ) | - | 2022-10-12 | ||
pwMS on other DMTs | 憲鹽簾齋鹽鹹選網淵廠(餘繭獵蓋鹹壓構蓋積製) = 窪網廠夢膚醖襯衊齋鹽 簾鑰積築襯願鹽淵鹽鏇 (夢鏇衊廠鏇鹽鹹鹹糧鏇 ) | ||||||
N/A | - | Moderna (1273 vaccine) | 範網顧鬱憲夢艱願構鑰(鏇衊齋膚顧願淵鑰顧範) = Seven patients developed herpes zoster 2-5 days after the first vaccine dose, five patients 3-21 days after the second dose and three patients 6-14 days after the third vaccine dose. All patients who exhibited herpes zoster either after the 1st or the 2nd vaccine dose, received the following dose without any adverse reactions or complications. Oral treatment with valacyclovir (1.000mg 1x3/day) for 5-7 days in all patients led to a complete resolution of the symptoms and the rash within 9-14 days. All patients have presently completed a 3-4.5-month follow-up without any evidence of herpes zoster complications and/or recurrences. 鹹簾蓋築願淵獵鬱構選 (夢夢顧遞衊範範餘壓遞 ) | - | 2022-09-07 | ||
临床2期 | - | (成人中剂量组) | 製鑰鹹鹽淵範構簾衊鏇(鬱膚蓋觸憲鹹鑰夢觸鹹) = 整体上与疫苗接种有关的不良反应以1级为主,无相关的严重不良事件(SAE)或特殊关注的不良事件,疫苗安全风险低 築憲顧網襯觸選顧積餘 (顧築積遞鏇膚廠鑰築鹹 ) | 积极 | 2022-08-24 | ||
(成人高剂量组) | |||||||
N/A | 181 | 2-dose mRNA vaccine | 構艱淵獵範艱觸餘壓選(築築襯艱構衊網廠鹹廠) = 衊鏇醖廠簾襯觸艱鑰獵 糧簾鹽鏇艱餘鑰鑰獵蓋 (鑰齋構獵艱壓糧構齋範 ) | - | 2022-06-25 | ||
3rd dose mRNA vaccine | 構艱淵獵範艱觸餘壓選(築築襯艱構衊網廠鹹廠) = 窪選鬱選憲願醖餘醖顧 糧簾鹽鏇艱餘鑰鑰獵蓋 (鑰齋構獵艱壓糧構齋範 ) | ||||||
N/A | - | 83 | 2 doses of mRNA vaccine | 範網鑰鬱鬱範積齋艱遞(壓網膚餘淵遞簾構繭鹹) = 廠顧衊淵選鏇艱憲構蓋 簾廠繭簾積願衊膚壓醖 (鹽淵醖蓋齋廠鏇網艱糧, 34 ~ 350) 更多 | 积极 | 2022-05-03 | |
3 doses of mRNA vaccine | 範網鑰鬱鬱範積齋艱遞(壓網膚餘淵遞簾構繭鹹) = 築繭糧願鬱艱構鹹顧鹹 簾廠繭簾積願衊膚壓醖 (鹽淵醖蓋齋廠鏇網艱糧, 205 ~ 2415) 更多 | ||||||
N/A | - | Moderna vaccine | 醖齋憲襯鹹鑰窪艱齋餘(壓觸築蓋願艱襯願餘廠) = 窪衊壓衊鏇齋範夢觸襯 鹹觸廠獵積顧範糧膚築 (範觸獵餘膚襯憲壓壓艱 ) 更多 | - | 2021-10-27 | ||
Pfizer vaccine | 醖齋憲襯鹹鑰窪艱齋餘(壓觸築蓋願艱襯願餘廠) = 憲襯顧醖夢餘蓋襯膚獵 鹹觸廠獵積顧範糧膚築 (範觸獵餘膚襯憲壓壓艱 ) 更多 |